CAMBRIDGE, Mass.--(BUSINESS WIRE)--MPM Capital (MPM) and Dana-Farber Cancer Institute have entered into a unique, first-of-its-kind, impact investing collaboration. The initiative partners fundraising ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--MPM Capital (MPM), an investor in innovative therapeutics companies, has announced the promotions of Shinichiro Fuse, Ph.D. and Kristen Laguerre to its Investment ...

Selexys Pharmaceuticals, Corp., announced today that it has successfully completed a $23 million Series A equity financing, led by MPM Capital. Additionally, Selexys entered into an agreement with ...

MPM Capital Closes $550 Million BioVentures IV Healthcare Venture Fund BOSTON & SAN FRANCISCO -- MPM Capital, L.P., a global investment management firm focused solely on healthcare investing, today ...

ZURICH, April 27 (Reuters) - A $471 million UBS venture fund aims to generate annual returns "north of 10 percent" for its European and Asian investors by financing new cancer drugs, helping speed ...

A life sciences-focused venture capital firm based near Boston has raised more than one-third of a billion dollars to invest in early-stage companies. Cambridge, Massachusetts-based MPM Capital said ...

TOKYO & SAN FRANCISCO–(BUSINESS WIRE)–Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) and DigiTx Partners LLC (CEO: David Kim, “DigiTx Partners”) announce that Astellas has ...

Semma Therapeutics, a company developing a cell therapy for Type 1 diabetes, announced today that it has closed a $44 million Series A consisting of equity financing and strategic funding. The Series ...

Steven St. Peter, managing director of MPM Capital, stands outside the former Ronald McDonald House, which soon will be the new home for MPM Capital. To continue ...

MPM Capital announced the close of its second oncology impact fund earlier this month, raising US$850 million to invest in companies—mostly early-stage—that are developing treatments and cures for ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--MPM Capital (MPM), a biotechnology investment firm investing in early-stage therapeutics companies, today announced that Pankaj Bhargava, MD has joined its team of ...

Life science VC MPM Capital is looking to boost funding for a select series of early-stage biotechs with a new $400 million fund. This cash injection comes from its seventh venture fund, known as ...